News & Events

See the latest news from Tango Biosciences, and check out where we’ll be next!

  • News

    NIH SBIR Award

    The National Institutes of Health (NIH) awarded a phase I grant to Tango Biosciences in January 2021. This award will support a collaborative effort that generates recombinant antibodies and antibody-like reagents for 6 SARS-CoV-2 viral proteins. These reagents will aid scientists in understanding the function of these viral proteins inside infected cells. Such information may […]

  • News

    Tango Biosciences publishes work on SARS-CoV-2 virus

    Tango Biosciences scientists, in collaboration with colleagues from B2S Life Sciences, LifeTein, and Euprotein, publish a scientific report on generating recombinant affinity reagents (monobodies) to the receptor binding domain (RBD) of the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. Soluble forms of the monobodies bound to several different preparations of the RBD and […]

  • News

    Society for Laboratory Automation & Screening Ignite Award

    Tango Biosciences was nominated as a finalist for the best start-up or emerging company. Named “one of the top 8 bioscience start-ups in 2019.”

  • News

    NIH STTR award

    In April 2018, Tango Biosciences received a R41 award from NIH. The goals of the grant are to generate two-site capable affinity reagents through MegaSTAR to two sets of targets. One set represents biomarkers of colorectal cancer and myocardial infarction. MegaSTAR reagents will be benchmarked against existing commercial sandwich reagents, and the performance metrics (i.e., […]